Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Significance: Multiple sclerosis (MS) is a chronic inflammatory and degenerative disease of the central nervous system (CNS) causing paralysis. The most effective treatments for MS aim to block infiltration of inflammatory cells to the brain. However, severe side effects related to the broad-acting specificity of these treatments exist. AZD8797, a unique inhibitor of the chemokine receptor CX3CR1, provides inhibition of subpopulations of peripheral leukocytes with potential for a beneficial effect: side effect ratio. We provide evidence that blocking this receptor results in reduced paralysis, inflammation, and degeneration in the CNS in a disease model for MS. Furthermore, CX3CR1 expression analysis in the MS brain strengthens the evidence for CX3CR1 as a new target for the treatment of MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Control of microglial neurotoxicity by the fractalkine receptor
Cardona, A. E., Pioro, E. P., Sasse, M. E., Kostenko, V., Cardona, S. M., Dijkstra, I. M., Huang, D., Kidd, G., Dombrowski, S., Dutta, R., et al. (2006) · Nature Neuroscience · doi:10.1038/nn1715 · Cited by 1,531
The relation between inflammation and neurodegeneration in multiple sclerosis brains
Frischer, J. M., Bramow, S., Dal-Bianco, A., Lucchinetti, C. F., Rauschka, H., Schmidbauer, M., Laursen, H., Sorensen, P. S., & Lassmann, H. (2009) · Brain · doi:10.1093/brain/awp070 · Cited by 1,450
Hughes, P. M., Botham, M. S., Frentzel, S., Mir, A., & Perry, V. H. (2002) · Glia · doi:10.1002/glia.10037 · Cited by 252
The blood-brain barrier, chemokines and multiple sclerosis
Holman, D. W., Klein, R. S., & Ransohoff, R. M. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2010.07.019 · Cited by 247 · cited 3×
“(2001) Targeted deletion of CX(3)CR1 reveals a role for fractalkine in”
BackgroundD'Haese, J. G., Demir, I. E., Friess, H., & Ceyhan, G. O. (2010) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728220903540265 · Cited by 116
Cited by
The role of chemokines and chemokine receptors in multiple sclerosis
Cui, L.-Y., Chu, S.-F., & Chen, N.-H. (2020) · International Immunopharmacology · doi:10.1016/j.intimp.2020.106314 · Cited by 135
Zanier, E. R., Marchesi, F., Ortolano, F., Perego, C., Arabian, M., Zoerle, T., Sammali, E., Pischiutta, F., & De Simoni, M.-G. (2016) · Journal of Neurotrauma · doi:10.1089/neu.2015.4041 · Cited by 94
Käufer, C., Chhatbar, C., Bröer, S., Waltl, I., Ghita, L., Gerhauser, I., Kalinke, U., & Löscher, W. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1806754115 · Cited by 61
Metadata
- Authors
- Ridderstad Wollberg, A., Ericsson-Dahlstrand, A., Juréus, A., Ekerot, P., Simon, S., Nilsson, M., Wiklund, S.-J., Berg, A.-L., Ferm, M., Sunnemark, D., & Johansson, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2014-03-25
- Volume
- 111
- Issue
- 14
- Pages
- 5409-5414
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2077943662
- Cited by
- 97
- References
- 5
- FWCI
- 4.36
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. https://app.cochat.ai/papers/10.1073/pnas.1316510111
- The paper
- Ridderstad Wollberg, A., Ericsson-Dahlstrand, A., Juréus, A., Ekerot, P., Simon, S., Nilsson, M., Wiklund, S.-J., Berg, A.-L., Ferm, M., Sunnemark, D., & Johansson, R. (2014). Pharmacological inhibition of the chemokine receptor CX3CR1 attenuates disease in a chronic-relapsing rat model for multiple sclerosis. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.1316510111
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.